
[
  {
    "question": "無解",
    "options": {
      "A": "相反。ITAM (activation)可促進免疫反應，ITIM (inhibition)可抑制免疫反應。",
      "B": "PD1有ITIM，因此anti-PD-1可防止ITIM抑制Tcell，促進Tcell殺死癌細胞。",
      "C": "TCR本身並沒有ITAM。TCR complex的ITAM來自ζ鏈的6個，加上兩組CD3各自帶的2個ITAM，總共10個ITAM。",
      "D": "Lck為tyrosine kinase。Lck本為磷酸化(去活化)狀態。TCR接觸抗原時，CD45會將Lck上的pTyr去磷酸化，活化Lck。"
    },
    "answer": null,
    "explanation": "［出自考古第1題］"
  },
  {
    "question": "(A)正確。",
    "options": {
      "A": "正確。",
      "B": "不是擋住抗原呈現細胞，是擋住免疫細胞(Tcell)的抑制訊號受體，讓Tcell不會被抑制。",
      "C": "CAR-T目前僅針對leukemia或其他血液腫瘤治療，尚未能應用至固體腫瘤治療。",
      "D": "Anti-CTLA-4與Anti-PD-1的作用機轉不完全相同。Anti-CTLA-4是針對Tcell接受抗原呈現時，擋住CTLA-4受器，使抗原呈現細胞的B7結合Tcell的CD28，活化Tcell。Anti-CD-1則是針對Tcell接觸癌細胞時，擋住Tcell的PD-1受器，使其不會被癌細胞的PD-L1抑制。兩種藥一起使用可能可以增強效果，但也更可能有自體免疫的副作用。"
    },
    "answer": "A",
    "explanation": "［出自考古第2題］"
  },
  {
    "question": "(A)AMPs由上皮組織與吞噬細胞製造。如:皮膚中的stratum spinosum、腸上皮中的Paneth cell.",
    "options": {
      "A": "AMPs由上皮組織與吞噬細胞製造。如:皮膚中的stratum spinosum、腸上皮中的Paneth cell.",
      "B": "AMPs製造出來時通常處於不活化狀態(Pro-AMP)，需要經蛋白酶切割pro-region後才能作用，稱為proteolysis.",
      "C": "AMPs為親疏水兩重性(amphipathic)多肽，可以穿入細胞膜並形成穿孔，不是細胞壁。",
      "D": "AMPs不具專一性。當細菌出現時，Pro-AMP才會被切割活化，因此才不會殺死host cell。另一種說法是，細菌細胞膜的結構相對於host cell更容易吸引AMPs."
    },
    "answer": "A",
    "explanation": "［出自考古第3題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": "Clr和C1s與MASP1、MASP2結構相近。MBL則是結構與C1q相近。",
      "B": "正確。",
      "C": "C3b不是inhibitor。Inhibitor(調節蛋白)是CR1、H，只有一般細胞上有。",
      "D": "C3a、C5a能促進吞噬細胞移動到感染、發炎區域。"
    },
    "answer": "B",
    "explanation": "［出自考古第4題］"
  },
  {
    "question": "(A)(D)",
    "options": {
      "A": "Correct.",
      "B": "IL-6 triggers acute phase responses through binding to hepatocytes (liver).",
      "C": "IFN-Is (IFN-α and IFN-β) are primarily induced by TLR-3 and TLR-7 signaling pathways and trigger antiviral response. IFN-γ (Type II IFN) is induced by TLR-4 signaling pathway triggered by the LPS of Gram-negative bacteria.",
      "D": "Correct."
    },
    "answer": [
      "A",
      "D"
    ],
    "explanation": "［出自考古第5題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": "TLRs are only expressed on plasma membrane and endosome.",
      "B": "Except for TLR3, all other TLRs signal through MyD88.",
      "C": "Correct.",
      "D": "TLR3 which binds dsRNA is located in endosome."
    },
    "answer": "C",
    "explanation": "［出自考古第6題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": "Both produce Lysozyme which digests cell walls of some Gram-positive bacteria.",
      "B": "Neutrophil can produce lactoferrin which competes Fe2+.",
      "C": "NETs contain elastase, myelo-peroxidase, cathepsin G and lactoferrin which degrade or block pathogens.",
      "D": "Correct."
    },
    "answer": "D",
    "explanation": "［出自考古第7題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": "Self-reactive T lymphocytes are deleted in the thymus.",
      "B": "The success of tissue transplantation depends on factors beyond CST, such as histocompatibility and immune suppression.",
      "C": "Correct.",
      "D": "CST was first proposed by Dr. Macfarlane Burnet (who later jointly received the Nobel Prize with Dr. Peter Medawar for the discovery of acquired immunological tolerance)."
    },
    "answer": "C",
    "explanation": "［出自考古第8題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": "應為PROMOTE light chain gene rearrangement.",
      "B": "應為STOP heavy chain gene rearrangement.",
      "C": "替代性輕鏈(SLC)僅作穩定使用，與基因重組無關。",
      "D": "正確，pre-Bcell訊號將可促成下游Bcell的成熟與分化。\n(參閱B10共筆vol.1第74頁下方Fig. 8.5)"
    },
    "answer": "D",
    "explanation": "［出自考古第9題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": "不會是一模一樣，是因兩種病毒關係相近，表面具有相似抗原，故對牛痘產生的抗體也能有效對抗天花。",
      "B": "因是天然未減毒的病毒株接種，所以引起免疫的效率確實比較好。",
      "C": "牛痘疫苗在1796年由Dr. Jenner發明，但天花一直到1979年才由WHO宣布根除，所以大概過了183年。",
      "D": "人痘接種(variolation)之風險來自於天然未減毒的病毒株直接接種，而非接種方式引起。\n(參閱B11共筆vol.1第6頁上方)"
    },
    "answer": "B",
    "explanation": "［出自考古第10題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": "在rearrangement of antigen receptor genes階段,兩者各自位在generative organ (骨髓/胸腺)。(B11 vol.1 第76頁)",
      "B": "Pre-BCR之替代輕鏈與pre-TCR之替代alpha鏈演化上相似。",
      "C": "接受過自體抗原受體檢查後,前驅B細胞才能發育為未成熟B細胞。題目有點繞口,直到未成熟階段前都不會開始=成熟階段前才開始。",
      "D": "是三道檢查點(必考,忘了請複習B11 vol.1第77頁)。"
    },
    "answer": "C",
    "explanation": "［出自考古第11題］"
  },
  {
    "question": "(A)",
    "options": {
      "A": "正確。(詳細可看B11 vol.1第86頁)",
      "B": "在小preB細胞階段時，輕鏈的V-J重排已完成，因而能做接下來的自體抗原測試。",
      "C": "IgM並未消失，而是多了IgD表現。",
      "D": "並非所有未通過自體抗原測試的Bcell都會被凋亡，可透過挽救機制:receptor editing重新基因重組。(詳細可看B11 vol.1第87頁，自體反應B細胞的4種命運)。"
    },
    "answer": "A",
    "explanation": "［出自考古第12題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": "ILCs是先天淋巴細胞(innate),與其它淋巴細胞一樣在骨髓生成(lymphoid lineage),並分佈於淋巴結與具有表皮組織的器官。",
      "B": "非T細胞亦非B細胞(沒有TCR,也沒有BCR),沒有抗原專一。",
      "C": "ILCs與對應的T細胞有類似的功能(overlapping cytokines)。",
      "D": "第三類免疫反應(type 3 response)針對胞外細菌及真菌,ILC3可製造IL-17 and IL-22 吸引與激活嗜中性球。"
    },
    "answer": "D",
    "explanation": "［出自考古第1題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": "$T_H$1 主要對付生長在巨噬細胞中的細菌，$T_H$1 細胞辨認病原後被活化，分泌細胞介素IFN-γ傳遞訊號。訊傳入巨噬細胞後會促使溶酶體(lysosome)和吞噬小體(phagosome)結合，形成吞噬溶酶體(phagolysosome),活化巨噬細胞消滅外來病原。",
      "B": "$T_H$2 對付胞外寄生蟲感染(helminth:蠕蟲)，並分泌IL-4、IL-13, 活化M2巨噬細胞,幫助組織修復。",
      "C": "$T_{FH}$位於B細胞濾泡(follicle),主要負責幫助B細胞的生發中心(GC)成熟。\nextracellular bacteria and fungi 是type 3 response, immune effector module包含group 3 ILCs、$T_H$17 $CD4^+$ T cell、IgG1、IgG2、嗜中性球。TNF-α 由被$T_H$1活化的巨噬細胞所產生。兩者皆非$T_{FH}$主導。",
      "D": "$T_{reg}$可分泌inhibitory cytokines (IL-10、TGF-β)抑制免疫系統。",
      "E": "胞毒性T細胞可清除被病毒感染的細胞,分泌穿孔素(perforin)使細胞穿孔、分泌顆粒酶(granzyme)使細胞內部物質被分解,進而發生細胞凋亡。"
    },
    "answer": "C",
    "explanation": "［出自考古第2題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": "免疫反應進程中的latent infection (潛伏感染):病原體並未在個體呈現出明顯病理反應及相關病原分泌物，但若免疫力降低時便會產生病理反應。",
      "B": "免疫系統產生的抗體具有血清型特異性(serotype-specific),而肺炎鏈球菌中構成莢膜的多醣只要稍微改變就會形成新的serotype,無法被過去感染的記憶細胞辨識。",
      "C": "免疫反應之間會互相影響,所以發生在一部分的免疫缺陷也可能造成其他免疫功能的異常。T細胞缺失常造成持續性真菌感染、病毒感染或是胞內細菌感染。",
      "D": "有些胞內細菌被巨噬細胞吞噬後,可以利用各種方法來阻斷吞噬小體(phagosome)和溶體(lysosome)兩者融合以分解細菌的機制。如結核桿菌(Mycobacterium tuberculosis),會將巨噬細胞當作特洛伊木馬,躲在其中,把巨噬細胞當成UBER,躲避免疫系統,因此只能將其暫時圍困住,時間長了仍有機會衝破封鎖造成疾病復發。",
      "E": "X-linked SCID是最常見的SCID,為IL2RG基因突變導致B細胞和T細胞的反應都消失,造成嚴重後天免疫缺乏,但仍保有先天免疫反應。"
    },
    "answer": "B",
    "explanation": "［出自考古第3題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": "減敏治療(desensitization):暴露低劑量的過敏原,並逐步增加劑量,讓免疫系統慢慢忍受過敏原,減少誘發IgE產生。",
      "B": "過敏可依反應時間分為2類:立即型與延遲型(DTH)。DTH由T細胞調控,接觸到過敏原後兩三天才出現過敏反應。",
      "C": "第一型過敏反應,肥大細胞活化後造成組織胺和其他媒介物遍布,血流及血管通透性(permeability)增加,體液外流到組織液中、血壓降低,輕則可能產生蕁麻疹(urticaria),重則過敏性休克(anaphylactic shock)。",
      "D": "麩質敏感性腸疾/乳糜瀉(gluten-sensitive enteropathy/celiac disease):攝取小麥穀蛋白或其他穀物的類似蛋白質,誘發T細胞去攻擊腸細胞,造成上皮細胞受傷。",
      "E": "同(B)。"
    },
    "answer": "B",
    "explanation": "［出自考古第4題］"
  },
  {
    "question": "(A)",
    "options": {
      "A": "過敏反應在進步國家的發生率較發展中國家高。",
      "B": "正確。",
      "C": "正確。",
      "D": "正確。",
      "E": "正確。"
    },
    "answer": "A",
    "explanation": "［出自考古第5題］"
  },
  {
    "question": "當後天免疫系統對於「無害抗原」起不適當的反應時，就會導致過敏，包含過敏症和自體免疫，而過敏案例通常複雜，可能結合多種機轉類型。",
    "options": {
      "T": "O",
      "F": "X"
    },
    "answer": "F",
    "explanation": "［出自考古第1題］"
  },
  {
    "question": "發炎是免疫反應的重要組成部分，有助於保護身體免受感染和損傷，有助於清除有害刺激，啟動治癒過程、對抗病原體。然而過度或持續的發炎確實可能是有害的，並導致各種疾病。",
    "options": {
      "T": "O",
      "F": "X"
    },
    "answer": "F",
    "explanation": "［出自考古第2題］"
  },
  {
    "question": "Type 1 hypersensitivity reaction is caused by an IgE-mediated immune response whose main physiological role is to defend against parasite infection.\n在組織中,IgE與肥大細胞(mast cell)的FcɛRI結合並活化之造成過敏;在血液中則結合嗜鹼性球(basophil)的FcɛRI。",
    "options": {
      "T": "O",
      "F": "X"
    },
    "answer": "F",
    "explanation": "［出自考古第3題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": "為class IMHC組裝過程。",
      "B": "應為$CD4^+$。",
      "C": "在lysosome裡進行結合。",
      "D": "正確。",
      "E": "為class IMHC組裝過程。"
    },
    "answer": "D",
    "explanation": "［出自考古第8題］"
  },
  {
    "question": "(C)\n腫瘤的演化分為三階段，其順序為清除(Elimination)、平衡(Equilibrium)、逃脫(Escape),故答案選(C)。\n以下為此三階段的詳細說明。(A) 清除(elimination):正常細胞癌化成腫瘤細胞時表現出腫瘤特定抗原(TSA, tumor-specific antigen),被免疫系統辨識並清除(immune surveillance)。(B) 平衡(equilibrium):還未被清除的腫瘤細胞一面突變、生長,一面和免疫系統對抗,增減維持一定平衡。(C) 逃脫(escape):不斷突變的結果,出現能逃過免疫系統辨識的細胞,開始不受控制生長,形成腫瘤。",
    "options": {
      "A": "(A) 清除(elimination):正常細胞癌化成腫瘤細胞時表現出腫瘤特定抗原(TSA, tumor-specific antigen),被免疫系統辨識並清除(immune surveillance)。",
      "B": "(B) 平衡(equilibrium):還未被清除的腫瘤細胞一面突變、生長,一面和免疫系統對抗,增減維持一定平衡。",
      "C": "(C) 逃脫(escape):不斷突變的結果,出現能逃過免疫系統辨識的細胞,開始不受控制生長，形成腫瘤。",
      "D": "Immunological synapse 可以分為兩個部分,核心處為cSMAC,周圍為"
    },
    "answer": "C",
    "explanation": "腫瘤的演化分為三階段,其順序為清除(Elimination)、平衡(Equilibrium)、逃脫(Escape),故答案選(C)。\n以下為此三階段的詳細說明。(A) 清除(elimination):正常細胞癌化成腫瘤細胞時表現出腫瘤特定抗原(TSA, tumor-specific antigen),被免疫系統辨識並清除(immune surveillance)。(B) 平衡(equilibrium):還未被清除的腫瘤細胞一面突變、生長,一面和免疫系統對抗,增減維持一定平衡。(C) 逃脫(escape):不斷突變的結果,出現能逃過免疫系統辨識的細胞,開始不受控制生長，形成腫瘤。\n［出自考古第9題］"
  },
  {
    "question": "(E)",
    "options": {
      "A": "(A)(B)(C)(D)皆為cold tumor的特性,而(E)選項之描述為hot tumor的特性\n(詳見B10共筆Vol. 4 p.44)。",
      "B": "(C)(E)正確,可參見B10共筆Vol. 3 p.26。(B)應為Cytotoxic T cells induce target cell apoptosis.",
      "C": null,
      "D": null,
      "E": "舉例來說，腫瘤細胞表面表現的PD-L1可與Tcell上的PD-1結合，抑制Tcell的活化。"
    },
    "answer": "E",
    "explanation": "［出自考古第11題］"
  },
  {
    "question": "(E)",
    "options": {
      "A": null,
      "B": null,
      "C": null,
      "D": null,
      "E": "Beta鏈重組發生在double negative的DN1、DN2期,DN3、DN4期則不發生重組。\nAlpha鏈重組發生在double positive期。\nRAG-1及RAG-2重組酶參與TCR alpha, beta鏈的基因重組。"
    },
    "answer": "E",
    "explanation": "［出自考古第2題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": null,
      "B": null,
      "C": null,
      "D": "發育中的Tcell若與自身抗原受體產生高強度結合(high avidity)反應，則進行淘汰。\n負選擇在thymocyte位於胸腺皮質時即開始，在胸腺皮質和髓質都會發生，但整體而言先做正選擇再做負選擇。\n負選擇和多種能進行抗原呈現的細胞有關，包含胸腺的皮質上皮細胞(cortical epithelial cell)、髓質上皮細胞(medullary epithelial cell)或源於骨髓的抗原呈現細胞(bone marrow derived APCs)如髓質樹突細胞、巨噬細胞等以上三種細胞。\nNegative choice的意義在於排除auto immune。"
    },
    "answer": "D",
    "explanation": "［出自考古第3題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": null,
      "B": null,
      "C": "無法辨識自身MHC抗原的Tcell會死亡。\n正選擇發生在胸腺皮質上皮細胞(thymic cortical epithelial cell)處,主要由皮質間質細胞(epithelial stroma cell)進行MHC抗原呈現供Tcell辨識。\n正選擇同時會決定Tcell的後續分化,當Tcell與兩種MHC之一的結合度較高,會誘導對應轉錄因子的產生,決定其輔助受體特異性,即transcriptional programming。\n正選擇訊號的產生需要TCR以及CD4, CD8 co-receptor合作產生Positive choice的意義在於MHC restriction。"
    },
    "answer": "C",
    "explanation": "［出自考古第4題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "自體免疫調節因子(AIRE, autoimmune regulator)在胸腺髓質中表現,誘發一般在周圍組織上才表現的蛋白質之表現,幫助負選擇進行。(共筆vol2 P65)",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "［出自考古第5題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "T細胞辨識的是線性多肽。因為只有線性多肽才與MHC的clefts結合,且與MHC結合的多肽在形成時,便已經喪失了蛋白質的構型。(共筆vol2 P75)",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "［出自考古第6題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": null,
      "B": null,
      "C": null,
      "D": "RAG-1 (Recombination-activating gene - 1) /RAG-2 複合物會與recombination signal sequence (RSS)結合並切割。以進行RAG- dependent\nV(D)J rearrangement。(共筆vol2 P97)",
      "E": null
    },
    "answer": "D",
    "explanation": "［出自考古第7題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": null,
      "B": null,
      "C": null,
      "D": "Immunological synapse 可以分為兩個部分,核心處為cSMAC,周圍為",
      "E": null
    },
    "answer": "D",
    "explanation": "［出自考古第10題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "PSMAC。(A) cSMAC: 除了具有T細胞上的TCR complex、$CD4^+$ 以及APC上的MHC,還分佈有其他costimulatory molecules,例如在T細胞上有CD28、CD2可以分別與APC上的B7.1(又稱CD80)、B7.2(又稱CD86)與LFA-3結合,這些都隸屬cSMAC的範圍。(B) pSMA:在T細胞上由LFA-1,APC上由ICAM-1組成,兩者有交互作用。",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "PSMAC。(A) cSMAC: 除了具有T細胞上的TCR complex、$CD4^+$ 以及APC上的MHC,還分佈有其他costimulatory molecules,例如在T細胞上有CD28、CD2可以分別與APC上的B7.1(又稱CD80)、B7.2(又稱CD86)與LFA-3結合,這些都隸屬cSMAC的範圍。(B) pSMA:在T細胞上由LFA-1,APC上由ICAM-1組成,兩者有交互作用。\n［出自考古第11題］"
  },
  {
    "question": "(CE)",
    "options": {
      "A": null,
      "B": null,
      "C": "(C)(E)正確,可參見B10共筆Vol. 3 p.26。(B)應為Cytotoxic T cells induce target cell apoptosis.",
      "D": null,
      "E": "(C)(E)正確,可參見B10共筆Vol. 3 p.26。(B)應為Cytotoxic T cells induce target cell apoptosis."
    },
    "answer": [
      "C",
      "E"
    ],
    "explanation": "［出自考古第12題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": null,
      "B": null,
      "C": null,
      "D": "重鏈及輕鏈各兩條組成了免疫球蛋白的Y字型結構,包含兩條臂(arm)及一個主幹(trunk)。(共筆vol2 P10)",
      "E": null
    },
    "answer": "D",
    "explanation": "［出自考古第1題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": null,
      "B": null,
      "C": null,
      "D": "木瓜酵素(papain):切在兩重鏈之間雙硫鍵的N端,產生兩條Fab及一條Fc,同時雙硫鍵仍留在Fc上。",
      "E": null
    },
    "answer": "D",
    "explanation": "［出自考古第2題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": null,
      "B": null,
      "C": "RAG-1 (Recombination-activating gene - 1)/RAG-2 複合物會與recombination signal sequence (RSS)結合並切割。以進行 RAG- dependent\nV(D)J rearrangement。(共筆vol2 P97)",
      "D": null,
      "E": null
    },
    "answer": "C",
    "explanation": "［出自考古第3題］"
  },
  {
    "question": "(A)應為continuous。",
    "options": {
      "A": "應為continuous。",
      "B": "(共筆vol2 P15)",
      "C": "圈環作為互補性決定區(CDRs),是辨識抗原的重要區域。六個HV圈環共同決定了一個抗原的結合位。(共筆vol2 P15)",
      "D": null,
      "E": null
    },
    "answer": "A",
    "explanation": "［出自考古第4題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "Antibody 的Fc region 並未與antigen結合。",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "［出自考古第5題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "(A)(C)(D)發生在germinal center的事件,通稱為germinal center reaction,如體細胞高度變異(somatic hypermutation)、抗體類型轉換重組(class switch\nrecombination)、親和力成熟(affinity maturation)。(詳見免疫學B11共筆Vol 2第35頁)",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "［出自考古第6題］"
  },
  {
    "question": "(D)",
    "options": {
      "A": null,
      "B": null,
      "C": null,
      "D": "依抗原是否可以和BCR crosslink,分為TI-1和TI-2,TI-1不可以,TI-2可以。(TI-1與TI-2例子詳見免疫學B11共筆第42頁表格)",
      "E": null
    },
    "answer": "D",
    "explanation": "［出自考古第7題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": "13價結合型肺炎鏈球菌疫苗,不活化疫苗。",
      "B": "人類乳突病毒疫苗,不活化疫苗。",
      "C": "麻疹腮腺炎德國麻疹混合疫苗,減毒疫苗。",
      "D": null,
      "E": null
    },
    "answer": "C",
    "explanation": "［出自考古第8題］"
  },
  {
    "question": "(C)",
    "options": {
      "A": null,
      "B": null,
      "C": "小兒麻痺病毒疫苗為不活化疫苗(inactivated polio vaccine),可以產生對抗病毒的抗體,可以防止小兒麻痺侵入中樞神經以及防止癱瘓。\nReference: IPV – GPEI (polioeradication.org)",
      "D": "季節性流感疫苗,不活化疫苗。",
      "E": null
    },
    "answer": "C",
    "explanation": "［出自考古第9題］"
  },
  {
    "question": "(A)",
    "options": {
      "A": "不在名單中。",
      "B": "alum為鉀鋁硫酸(Potassium Aluminum Sulfate),鋁鹽為常見的佐劑,廣泛用於許多疫苗中——數量太多族繁不及備載,故不一一列出。鋁鹽的功能目前眾說紛紜,較為人接受的解釋為鋁鹽可以協助吸附、逐步釋放抗原,而近期也有研究指出鋁鹽可以刺激免疫細胞(包括巨噬細胞、樹突細胞),可以調節免疫功能。",
      "C": "此類佐劑為透過調節疫苗傳送系統的釋放效果增進疫苗的效力。大致上為使疫苗被油脂包裹住,使其能夠被油脂保護住直到被吞噬細胞吞噬。這種配方被稱為MF59,是透過角鯊烯與水形成乳液懸滴,使其能夠被吞噬細胞有效吞噬。",
      "D": "此類佐劑為增進免疫誘導力,透過TLR-9與CpG的結合,誘導吞噬細胞吞入疫苗以促進疫苗的效力。",
      "E": null
    },
    "answer": "A",
    "explanation": "［出自考古第10題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "$T_H$2為特化的effector T cell,是用以對抗寄生蟲(parasites)、蠕蟲\n(helminths)的手段,會透過分泌IL-4、IL-13 進而誘導嗜酸性球、嗜鹼性球、肥大細胞作用。",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "［出自考古第11題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "CAR-T 仰賴基因工程,利用Lentivirus(一種反轉錄病毒)使表現謙和抗原受體——可引導基因編輯後的T細胞找到癌細胞——後在送回體內。\n而編輯後的嵌合抗原受體包刮Costimulatory domain,如CD28、4-1BB,以及signal domain,如$CD3ζ$。",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "［出自考古第12題］"
  },
  {
    "question": "(B)",
    "options": {
      "A": null,
      "B": "正確的說法應該是，活性減毒疫苗通常是通過減毒過程製造的，這個過程中，病原體會被削弱，但它仍然是活著的。",
      "C": null,
      "D": null,
      "E": null
    },
    "answer": "B",
    "explanation": "［出自考古第13題］"
  }
]
